BioSource board spurns Bio-Rad offer
This article was originally published in Clinica
The board of directors of BioSource International has voted unanimously to reject Bio-Rad's $8.50 per share unsolicited takeover bid for the company (see Clinica No 1152, p 13). It decided that the offer was "significantly below BioSource's inherent value", following consultation with legal and financial advisors.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.